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Abstract
Glomus tumors are rare skull base slow-growing, hypervascular neoplasms that frequently involve critical
neurovascular structures, and delay in diagnosis is frequent. Surgical removal is rarely radical and is usually
associated with morbidity or mortality. Gamma knife surgery (GKS) has gained an increasing dependable role in the
management of glomus jugulare tumors, with high rate of tumor growth control, preserving or improving clinical
status and with limited complications. This study aims to evaluate intermediate term benefits and complications of
gamma knife surgery in management of twenty-two patients bearing growing glomus jugulare tumors at the
International Medical Center (IMC), Cairo, Egypt, between 2005 and 2011. The mean follow-up period was
56 months (range 36–108 months); there were 3 males, 19 females; mean age was 43.6 years; 15 patients had GKS
as the primary treatment; 2 patients had surgical residuals; 2 had previous radiation therapy; and 3 previously
underwent endovascular embolization. The average tumor volume was 7.26 cm3, and the mean marginal dose was
14.7 Gy. Post gamma knife surgery through the follow-up period neurological status was improved in 12 patients, 7
showed stable clinical condition and 3 patients developed new moderate deficits. Tumor volume post GKS was
unchanged in 13 patients, decreased in 8, and showed tumor regrowth in 1 patient. Tumor progression-free
survival in our studied patients was 95.5 % at 5 and 7 years of the follow-up period post GKS. Gamma knife surgery
could be used safely and effectively with limited complications as a primary management tool in the treatment of
glomus jugulare tumors controlling tumor growth with preserving or improving clinical status especially those who
do not have significant cranial or cervical extension, elderly, and surgically unfit patients; moreover, it is safe and
highly effective as adjuvant therapy as well.
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Background
Glomus tumors are rare skull base benign slow-growing,
highly vascular locally invasive tumors, also known as
paragangliomas or chemodectomas. They originate from
preganglionic tissues that can be found in the adventitia
of the jugular bulb (glomus jugulare). These rare tumors
reportedly occur predominantly in women, in a ratio of
1:1,000,000, in the sixth and seventh decade of life [1–5].
Although mostly benign and slow-growing, glomus
jugulare tumors have a high propensity for local invasion
of adjacent vascular structures, lower cranial nerves,
middle ear, petrous apex, cavernous sinus, inner ear,
carotid canal, or even up to infratemporal fossa, which
may result in substantial morbidity and often complicate
the surgical management of these tumors. The operative
approach is complicated by the fact that lesions may be
both intradural and extradural even with cervical com-
ponents, with engulfment of critical neurovascular struc-
tures. Thus, it is not surprising that resection entails a
great deal of morbidity or mortality and leaves behind
usually large residual tumors [2, 4–7].
The most common symptoms are pulsatile tinnitus,
conductive deafness, hypoacusis, headache, vertigo, and
multiple cranial nerve palsy with possible involvement of
5th to 12th cranial nerves. The neurological symptoms
are related to the region affected by the tumor. This can
infiltrate neurovascular structures, the temporal bone,
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the jugular foramen, the hypoglossal canal, the clivus,
the cavernous sinus, and cervical region [1, 2, 5–8].
Cranial nerve involvement produces hoarseness and
dysphagia. The presence of jugular foramen syndrome
(paresis of cranial nerves IX–XI) is pathognomonic for
this tumor, but it usually follows the initial symptoms of
decreasing hearing and pulsatile tinnitus. Less com-
monly, glomus tumors produce facial nerve palsy, hypo-
glossal nerve palsy, or Horner syndrome. Ataxia and
brain stem symptoms may infrequently develop [2, 9–
12, 16].
Treatment strategies for glomus jugulare tumors in-
clude microsurgery, preoperative embolization followed
by surgical resection, fractionated external beam radio-
therapy, and radiosurgery in the form of gamma knife
radiosurgery. The use of various procedures may be the
result of planned staging, or procedures may be used in
combination as a salvage treatment after recurrence or
progression. Although glomus cells are radio-resistant
yet, radiotherapy helps decrease tumor growth by indu-
cing fibrosis around the supplying vessels (endarteritis
obliterance) [12, 13, 15].
Gamma knife surgery has been proposed as an alterna-
tive to conventional external beam radiotherapy as it has
the capability of delivering precise high-dose radiation to
a small localized field increasing the chances of oblitera-
tive endarteritis while reducing complications by sparing
adjacent normal structures [10, 12, 14, 15].
Material and method
Objective
This study aims to evaluate an intermediate term bene-
fits and complications of gamma knife surgery in the
treatment of glomus jugulare tumors and its role as a
primary modality of treatment.
Method
A retrospective review was undertaken of the results ob-
tained in 22 patients harboring glomus jugulare tumors
that underwent gamma knife surgery (GKS) for recur-
rent, residual, or unrespectable tumors at the Inter-
national Medical Center (IMC), Cairo, Egypt, from
beginning of 2005 and end of 2011. The median clinical
and radiological follow-up period was 56 months ranged
(36–108 months). All patients underwent complete
neurological assessment, examination before the treat-
ment with MRI and audiograms. Follow-up includes
clinical neurological evaluation and MRI brain with con-
trast. The follow-up post gamma knife done regularly
each 6 months in the first year then yearly afterward.
In our studied 22 patients with glomus jugulare tu-
mors,15 patients underwent gamma knife surgery as pri-
mary treatment and used as adjuvant therapy for 7
patients. In those treated with gamma knife as adjuvant
therapy, 2 had previous partial microsurgical tumor re-
moval with sizable residuals, another 2 had previous
treatment with fractionated radiation therapy (typical
45–50 Gy) with regrowth of their tumors with in 12 and
18 months. Another 3 patients had endovascular
embolization prior to GKS for their large hypervascular
tumor volumes (19.4, 16, and 14.2 cm3), as preparation
for microsurgery where two of them surgically operated
before GKS leaving sizable residuals and one presented
directly to GKS.
Radiosurgery technique
The Elekta Leksell gamma knife version B model used
before the beginning of 2010 then the 4-C version used
afterward for the treatment of studied 22 patients with
glomus jugulare tumors. The stereotactic frame was
placed as low as posterior and as much to the side of the
lesion with the head in a position of flexion. Target
localization was achieved using MRI with contrast per-
formed with T1 axial and coronal-weighted sequence at
2-mm slice thickness on zero angle without gap. T1-fat
subtraction and also T2 axial sequence were also used to
eliminate tumor edema, bone, fat, and embolized mater-
ial if used. Treatment planning performed using Elekta
Leksell Gamma Plan Version 10.1.
The mean tumor volume in our treated 22 patients
was 7.26 cm3 (range 2.8–19.4 cm3). The mean tumor
peripheral dose was 14.7 Gy (ranged 12–16 Gy), the
mean isodose curve was 37.7 % (range 35 to 50 %), and
the mean maximum tumor dose was 41 Gy (34–45 Gy),
with a mean tumor radiation coverage of 96.3 % by the
prescribed dose. Adjacent area of brain stem dose
ranged between 10–12 Gy.
Results
The mean age of patients was 46.8 years (range 22–
72 years). There were19 females and 3 males. The tu-
mors were located at the left side in 15 patients and
right side in 7 patients (Table 1).
The most common neurological deficit at initial evalu-
ation was bulbar symptoms (IX, X, XI cranial nerve par-
esis) in 15 patients, deterioration in hearing up to
hearing loss in 8, facial nerve palsy in 1 patient (previ-
ously had microsurgical resection), pulsatile tinnitus in
12 patients, and tongue deviation with wasting (XII par-
esis) in 1 patient. Shoulder pain, neck pain, and trigemi-
nal symptoms also detected.
Clinical improvement was detected in 12 patients dur-
ing the follow-up period, improving starting within
12 months to 24 months post GKS, and was mainly in
bulbar symptoms (dysphonia, regurgitation),followed by
tinnitus and also shoulder pain; 7 patients showed stable
clinical condition with no additional symptoms or signs.
Three patients developed new neurological deficit post
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gamma knife treatment, one developed transient facial
nerve palsy, one developed trigeminal pain that
responded to medical treatment, and one developed
hearing loss in addition to facial numbness.
Regarding tumor size in the follow-up MRI brain in
our study 22 patients, 8 showed some tumor size
reduction; the radiation coverage of their tumors was
above 95 %, marginal prescribed dose was 15–16 Gy,
and 13 patients had local tumor control (Figs. 1 and 2.)
One patient showed progressive tumor growth in this
study (the tumor volume was 19.4 cm3; it was large
postoperative residual and 90 % of the tumor covered by
12 Gy prescription marginal dose); the patient was
retreated with gamma knife after 4 years of initial GKS
treatment.
Tumor progression-free survival after GKS in our
study was 95.5 % at 5 and 7 years of follow-up period.
Discussion
Glomus jugulare tumors are slowly growing, locally de-
structive, highly vascular lesions located in one of the
most poorly accessible surgical regions of the skull base
mainly. The operative approach is, in addition, compli-
cated by the fact that lesions may be both intradural
intracranial and extradural with engulfment of critical
neurovascular structures, may invade the jugular for-
amen, and may extend extra cranially within the upper
cervical region; thus, it is not surprising that resection
entails a great deal of morbidity and leaves behind usu-
ally large residual tumors [2, 3, 6, 9, 13].
Among the 22 glomus jugulare tumor patients in our
series, 15 patients underwent gamma knife surgery as
primary treatment, and 7 patients had GKS as adjuvant
Table 1 Characteristics of the studied 22 patients undergoing
GKS for glmous jugulare tumors
Parameter value
Total no. of patients: 22
Female 19
Male 3
Age (range) 22–72 years (mean 46.8 years)











Ranged 2.8–19.4 cm3(mean volume is
7.26 cm3)
Follow-up period: Ranged 36–108 months(mean is 56 ms)
Fig. 1 a Pre-gamma knife stereotactic contrast enhanced MR image of a female patient with a large 7.4 cm3 left glomus jugulare treated with
15 Gy marginal dose to 35 % isodose line with 98 % coverage with the prescribed dose. b Contrast-enhanced MR image of the same patient
96 months after GKS showing significant tumor regression
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therapy. The mean age of patients was 46.8 years (range,
22–72 years); there were 19 females and 3 males.
In our study, the most common neurological deficit at
initial evaluation was bulbar symptoms (IX, X, XI cranial
nerve paresis) that detected in 15 patients, pulsatile tin-
nitus in 12 patients, deterioration in hearing in 8 pa-
tients, VII nerve palsy in 1, and tongue deviation (XII
paresis) in 1 patient.
The most frequent symptoms of glomus jugulare tu-
mors include pulsatile, tinnitus, conductive deafness,
headache, migraine, hypoacusis, vertigo, and multiple
cranial nerve palsy, with possible involvement of 5th to
12th cranial nerves. The neurological symptoms are re-
lated to the region affected by the tumor. This can infil-
trate neurovascular structures, the temporal bone, the
jugular foramen, the hypoglossal canal, the clivus, the
cavernous sinus, and cervical region [1, 2, 6, 9, 14].
Green et al. showed their surgical experience with 52
previously untreated patients with glomus jugulare tu-
mors. Lower cranial nerve preservation was possible in
the majority of patients with normal preoperative func-
tion. Most patients (85 %) were able to fully resume all
preoperative activities. Their results suggested that surgi-
cal management is an important option in younger pa-
tients with glomus jugulare tumors. Nevertheless, many
cases postoperative have tumor residuals [7].
Gerosa et al. 2006, between 1996 and 2005, used GKS
to treat 20 patients bearing growing glomus jugulare tu-
mors with average follow-up 50, 85 months; 3 patients
received GKS as primary treatment, 8 had surgical re-
currences, and 11 out of the 20 patients previously
underwent endovascular embolization. Neurological
signs and symptoms were unchanged in 13 patients. An
improvement of cranial nerve function was observed in
5 patients. For gamma knife complications, hearing de-
terioration was observed in 2 patients. Tumor volume
was unchanged in 11 patients and was slightly decreased
in 8 patients [5].
Sheehan et al. (2012) in a review under the guidance
of the North American Gamma Knife Consortium, 8
gamma knife surgery centers that treat glomus tumors
combined their outcome data retrospectively. One hun-
dred thirty-four patient procedures were included in the
study. Prior resection was performed in 51 patients, and
prior fractionated radiotherapy was performed in 6 pa-
tients. The patients’ median age was 59 years. Forty had
pulsatile tinnitus at the time of GKS. The median dose
to the tumor margin was 15 Gy. The median of follow-
up period was 50.5 months. Overall tumor control was
achieved in 93 % of patients; actuarial tumor control rate
was 88 % at 5 years post radiosurgery. Pulsatile tinnitus
improved in 49 % of patients. New cranial nerve deficits
were noted in 15 %; improvement in preexisting cranial
nerve deficits was observed in 11 % of patients [14].
Liscak et al. (2014), during the period from 1992 to
2003, treated 46 patients with glomus jugulare tumors
with the median age of 56 years. GKS was the primary
treatment in 17 patients (37 %). Open surgery preceded
gamma knife stereotactic radiosurgery in 46 % of cases,
embolization in 17 %, and fractionated radiotherapy in
4 %. The volume of the tumor ranged from 0.2 to
24.3 cm3, dose to the tumor margin ranged between 10
Fig. 2 a Pre-gamma knife stereotactic contrast-enhanced MR image of a patient with a large 6 cm3 left glomus jugulare treated with 15 Gy
marginal dose to 35 % isodose line with 97 % coverage with the prescribed dose. b Contrast-enhanced MR image of the same patient 72 months
after GKS showing some tumor regression
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and 30 Gy, and median follow-up period was
118 months. Neurological deficits improved in 19 of 45
patients and deteriorated in 2 patients. Tumor size de-
creased in 34 of 44 patients with imaging follow-up,
while an increase in volume was observed in 1 patient
[9].
In our studied 22 glomus jugulare patients subjected
to gamma knife surgery, the median clinical and radio-
logical follow-up period was 56 months ranged between
36 and 108 months. The mean tumor volume was
7.26 cm3, the mean tumor peripheral dose was 14.7 Gy,
the mean isodose curve was 37.7 %, and the mean max-
imum dose to the tumor was 41 Gy. Clinical improve-
ment was detected in 12 patients during the follow-up
period; improvement was mainly in bulbar symptoms
(dysphonia, regurgitation) followed by tinnitus and also
shoulder pain; 7 patients showed stable clinical condi-
tion. Regarding post gamma knife complications, 3 pa-
tients experienced new deficits, 1 developed transient
facial nerve palsy, another developed trigeminal pain
that responded to medical treatment, and 1 patient de-
veloped hearing loss in addition to facial numbness
Regarding tumor size in follow-up MRI in our studied
22 patients, 8 showed some tumor size reduction, 13
had local tumor control (stable), and 1 patient showed
progressive tumor growth (who had large postoperative
residual of 19.4 cm3 volume and 90 % coverage of given
12 Gy prescription marginal dose). This patient was
retreated with gamma knife 4 years after initial treat-
ment. Tumor progression-free survival after GKS in our
study was 100 % at 3 years and 95.5 % at 5 and 7 years
of follow-up period.
Conclusions
Gamma knife surgery could be used safely and effect-
ively with limited side effects as a primary management
tool in patients with glomus jugulare tumors especially
those who have no significant cranial or cervical exten-
sion, in the elderly, and in patients with serious preexist-
ing medical conditions, while it is also safe and effective
as adjuvant therapy after surgical debulking and or post
endovascular embolization. Despite of the limited num-
ber of the studied patients with glomus jugulare tumors
(22 patients),GKS would seem to afford effective local
tumor control and preserves neurological function with
mean follow-up of 56 months (range 36–108 months),
GKS role as primary management likely established as a
valid alternative to surgery in selected patients.
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